Ignite Creation Date:
2024-05-05 @ 12:06 PM
Last Modification Date:
2024-10-26 @ 9:20 AM
Study NCT ID:
NCT00245635
Status:
COMPLETED
Last Update Posted:
2018-04-27
First Post:
2005-10-26
Brief Title:
Fluoxetine in Pediatric Body Dysmorphic Disorder
Sponsor:
Montefiore Medical Center
Organization:
Montefiore Medical Center
Study Overview
Official Title:
Fluoxetine in Pediatric Body Dysmorphic Disorder
Status:
COMPLETED
Status Verified Date:
2018-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
FDA BDD
Brief Summary:
This trial will study the effectiveness of the medication fluoxetine for children and adolescents ages 16 and younger with BDD who qualify
Detailed Description:
BDD usually begins in childhood or adolescence but its treatment in pediatric populations has not been investigated Recent data suggests that adults with BDD may respond to serotonin reuptake inhibitors SRIs such as fluoxetine Prozac Preliminary findings from case reports suggest that SRIs may also be effective in the treatment of BDD in children and adolescents This study is the first large-scale double-blind placebo-controlled medication trial of fluoxetine for children and adolescents with BDD Participants should be aged 16 or younger Participation in this trial will last approximately 14 weeks
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
True
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 7R01FD002613-04 | FDA | None | httpsreporternihgovquickSearch7R01FD002613-04 |